Treatment of bile duct‐ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension
- 15 February 2008
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 28 (3) , 331-338
Abstract
Aim: Nitric oxide levels are decreased in the cirrhotic liver and increased in the systemic vasculature. We investigated whether the nitric oxide synthase (NOS) transcription enhancer AVE 9488 ameliorates portal hypertension in cirrhotic rats.Methods: Rats with secondary biliary cirrhosis [bile duct ligation (BDL)] were treated with AVE 9488. BDL animals without treatment served as controls. Blood flow was determined with the microsphere technique. Intrahepatic resistance was measured by in situ perfusion. NOS‐3 mRNA and protein levels in the liver, aorta and superior mesenteric artery (SMA) were measured.Results: Arterial pressure did not differ between treated and non‐treated animals. Portal pressure, hepatic portal‐vascular resistance and perfusion pressure of the in situ perfused liver were lower in the AVE 9488‐treated animals. Arterial splanchnic resistance, portal venous inflow and shunt volume were increased by AVE 9488. N (G)‐nitro‐l‐arginine methyl ester abolished the effect of AVE 9488. AVE 9488‐treated rats had higher liver NOS‐3 mRNA and protein levels, whereas NOS‐3 mRNA and protein in the aorta and the SMA did not vary between groups. Phosphorylation of liver vasodilator‐stimulated phosphoprotein (VASP) and NOS‐3 as well as hepatic nitrite/nitrate was increased by AVE 9488.Conclusions: Treatment of BDL rats with the NOS transcription enhancer AVE 9488 induces an increase in NOS‐3 mRNA and protein in the liver. This is associated with an amelioration of portal hypertension.Keywords
This publication has 27 references indexed in Scilit:
- Long-Term Treatment of Bile Duct-Ligated Rats with Rapamycin (Sirolimus) Significantly Attenuates Liver Fibrosis: Analysis of the Underlying MechanismsThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Vasodilator mRNA levels are increased in the livers of portal hypertensive NO‐synthase 3‐deficient miceEuropean Journal of Clinical Investigation, 2004
- Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat liversHepatology, 2002
- The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enoughHepatology, 2002
- Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertensionJournal of Clinical Investigation, 2000
- Hepatic and splanchnic nitric oxide activity in patients with cirrhosisGut, 1999
- Targeting Nitric Oxide (NO) Deliveryin Vivo. Design of a Liver-Selective NO Donor Prodrug That Blocks Tumor Necrosis Factor-α-Induced Apoptosis and Toxicity in the LiverJournal of Medicinal Chemistry, 1997
- Decreased constitutive hepatic nitric oxide synthase expression in secondary biliary fibrosis and its changes after Roux-en-Y choledocho-jejunostomy in the ratJournal of Hepatology, 1996
- The Golgi Association of Endothelial Nitric Oxide Synthase Is Necessary for the Efficient Synthesis of Nitric OxideJournal of Biological Chemistry, 1995
- Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility.Journal of Clinical Investigation, 1995